Entrada Therapeutics (TRDA) Research & Development (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Research & Development of $33.1 million for Q1 2026, up 3.06% year-over-year from $32.1 million in Q1 2025, and down 2.66% quarter-over-quarter from $34.0 million in Q4 2025.
Entrada Therapeutics (TRDA) Research & Development (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.1 million for Q1 2026.
- In Q1 2026, Research & Development rose 3.06% year-over-year to $33.1 million; the TTM figure through Mar 2026 stood at $143.2 million (up 11.24% YoY), while the FY2025 annual figure was $142.3 million, up 13.54% from the prior year.
- Research & Development for Q1 2026 stood at $33.1 million, down from $34.0 million in the prior quarter.
- The five-year high for Research & Development was $38.4 million in Q3 2025, with the low at $15.7 million in Q4 2022.
- The 5-year median for Research & Development is $28.6 million (2024), against an average of $27.5 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 152.58% in 2022, then increased 1.65% in 2025.
- Entrada Therapeutics' Research & Development stood at $15.7 million in 2022, then soared by 80.37% to $28.3 million in 2023, then climbed by 18.08% to $33.4 million in 2024, then advanced by 1.65% to $34.0 million in 2025, then dropped by 2.66% to $33.1 million in 2026.
- Business Quant data shows TRDA's Research & Development at $33.1 million in Q1 2026, $34.0 million in Q4 2025, and $38.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 35.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.37 Mn |
| Mar 31, 2026 | 33.05 Mn |
| Dec 31, 2025 | 33.96 Mn |
| Sep 30, 2025 | 38.36 Mn |
| Jun 30, 2025 | 37.88 Mn |
| Mar 31, 2025 | 32.07 Mn |
| Dec 31, 2024 | 33.41 Mn |
| Sep 30, 2024 | 31.26 Mn |
| Jun 30, 2024 | 32.04 Mn |
| Mar 31, 2024 | 28.61 Mn |
| Dec 31, 2023 | 28.29 Mn |
| Sep 30, 2023 | 22.19 Mn |
| Jun 30, 2023 | 26.30 Mn |
| Mar 31, 2023 | 23.10 Mn |
| Dec 31, 2022 | 15.69 Mn |
| Sep 30, 2022 | 18.96 Mn |
| Jun 30, 2022 | 16.25 Mn |
| Mar 31, 2022 | 15.72 Mn |
| Dec 31, 2021 | 12.36 Mn |
| Sep 30, 2021 | 10.51 Mn |